| Previous Close | 19.57 |
| Open | 19.67 |
| Bid | 19.54 x 0 |
| Ask | 19.54 x 0 |
| Day's Range | 19.48 - 19.94 |
| 52 Week Range | 7.33 - 32.95 |
| Volume | 478,137 |
| Avg. Volume | 1,021,588 |
| Market Cap | 6.551B |
| Beta (3Y Monthly) | 4.95 |
| PE Ratio (TTM) | 35.27 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into an agreement to acquire an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada from Apotex Fermentation Inc. (“AFI”). As previously announced, Cronos Group has entered into a partnership with Ginkgo Bioworks, Inc. (“Ginkgo”) to produce cultured cannabinoids.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that Dr. Todd Abraham has been appointed as the Company’s Chief Innovation Officer. In this role, Dr. Abraham will be responsible for advancing Cronos Group’s research and development initiatives in cannabinoids with a focus on identifying new disruptive technologies and adopting best practices and innovations from adjacent consumer goods industries.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results for the second quarter ended June 30, 2019, and hold its Second Quarter 2019 Earnings Conference Call on Thursday, August 8, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) reports that at its Annual Meeting of Shareholders on June 19, 2019 there were 610 shareholders voting in person or by proxy holding in total 261,290,314 common shares, representing 78.2% of the total number of common shares outstanding.
Cronos Group Inc. (“Cronos Group” or the “Company”) (CRON.TO) (CRON.TO), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at three industry conferences in June. Mr. Gorenstein will present at the Piper Jaffray 39th Annual Consumer Marketplace Conference on Thursday June 6, 2019 at 1:30 p.m. ET in New York, NY, the Jefferies 2019 Healthcare Conference on Friday June 7, 2019 at 11:30 a.m. ET in New York, NY and the Stifel 2019 Cross Sector Insight Conference on Wednesday June 12, 2019 at 1:15 p.m. ET in Boston, MA. The presentations will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, will hold its 2019 Annual Meeting of Shareholders on Wednesday, June 19, 2019 at 10 a.m. ET at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto. The Notice of Meeting and Management Information Circular are available on the Governance section of the Company’s website at https://ir.thecronosgroup.com/investor-relations. A live audio webcast and replay of the meeting will also be available in the Investor Relations section of the Company’s website.
MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.
Cronos Group Closes C$2.4 Billion Strategic Investment from Altria Group Cronos Group Establishes Cronos Device Labs, a State-of-the-Art Vaporizer R&D Initiative NatuEra.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it is expanding its global infrastructure network and innovation capabilities with the opening of a cannabinoid device R&D facility, based in Israel (“Cronos Device Labs”). The state-of-the-art facility supports Cronos Group’s efforts to develop next-generation vaporizer products that are designed specifically for cannabinoid applications. Cronos Device Labs, which is equipped with an experienced team of product development talent, advanced vaporizer technology and analytical testing infrastructure, serves as the global center of R&D for the Company’s vaporizer devices.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 02, 2019 -- Water Ways Technologies Inc. (TSXV: WWT) ("Water Ways" or the.
DENVER , April 17, 2019 /CNW/ -- Ever since the Farm Bill was signed into law, farmers across the United States have rushed into hemp cultivation, driving demand for the supplies needed to grow the crop necessary to meet surging CBD use. Global hemp industry to reach $22 billion in 2022. Hemp is booming across the country, and nowhere more so than in Kentucky , where the applications to grow hemp are expected to increase fivefold, and acreage dedicated to growing the crop is set to more than triple this year.
Water Ways Technologies Inc. (WWT.V) ("Water Ways" or the "Company"), is pleased to provide a business update from the Company's founder and chief executive officer Mr. Ohad Haber. On behalf of the Company I wish to thank you for your support.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results for the first quarter ended March 31, 2019, and hold its First Quarter 2019 Earnings Conference Call on Thursday, May 9, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.
CORAL GABLES, FL / ACCESSWIRE / April 4, 2019 / When speaking about the marijuana stock market, one cannot help but bring into the conversation the importance of companies with ancillary functions in the cannabis sector. ParcelPal Technology Inc (PTNYF) (PKG), Innovative Industrial Properties Inc (IIPR), Charlotte's Web Holding Corp (CWBHF), and Cronos Group Inc (NASDAQ: CRON, TSX: CRON) are 4 pot stocks heating things up on Thursday. ParcelPal Technology Inc (PTNYF) (PKG) today announced that the Company will be hosting an investor update conference call on May 17th, 2019 for the purpose of reviewing the Company's recent progress as well as provide investors with plans for the future.
Cannabis retail has rapidly emerged as one of the most important components of the marijuana value chain. Not only do retail gatekeepers control one of the most intimate parts of the cannabis purchasing experience, but they do so at a premium — making cannabis retail a likely determinant of any marijuana company’s staying power. In this article, we explore some of the leading cannabis retail brands in Canada.
Closed C$2.4 Billion Strategic Growth Investment from Altria Group, Inc. Completed first harvest in Peace Naturals expansion to Building 4 Launched Two Recreational.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that the C$2.4 billion equity investment in the Company by Altria Group, Inc. (MO) (“Altria”) has closed. As previously announced, Altria’s investment represents an approximate 45% ownership interest in Cronos Group.
Altria’s investment represents an approximate 45% economic and voting interest in Cronos Group with a warrant to acquire additional ownership at a price of CAD $19.00 per share, exercisable over the next four years. If exercised in full today, the warrant would increase Altria’s ownership in Cronos Group to approximately 55%. Under the terms of the transaction, Altria nominated four directors who were recently elected to serve on Cronos Group’s seven member board: Kevin C. Crosthwaite, Jr., Murray R. Garnick, Bruce A. Gates and Bronwen Evans.
CORAL GABLES, FL / ACCESSWIRE / March 5, 2019 / The marijuana stock market has become the focal point of conversation over the course of the past few years, resulting in a bullish run for companies in the cannabis industry. Over that time period, countless new companies in the industry have gained notoriety for their innovative approaches to creating cannabis products for consumers. With the majority of U.S. states having some form of legal cannabis, either recreational or medicinal, the marijuana industry is whirring with excitement.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), confirmed today that it has sold all of its common shares in the capital of Whistler Medical Marijuana Corporation ("Whistler"), representing approximately 19 percent of Whistler’s issued and outstanding common shares, to Aurora Cannabis Inc. (“Aurora”) for a total purchase price of approximately C$175 million, payable by the issuance of common shares in the capital of Aurora (“Aurora Common Shares”), and subject to certain working capital adjustments and holdbacks (the “Transaction”).
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results and hold its Full Year and Fourth Quarter 2018 Earnings Conference Call on Tuesday, March 26, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://thecronosgroup.com/investor-relations. The call will be archived on the Company’s website for replay.
CORAL GABLES, FL / ACCESSWIRE / February 28, 2019 / The marijuana stock market has seen impressive growth in the first few months of the new year. Since the passing of the US Farm Bill, companies in the cannabis industry have been working to build out their hemp operations and manufacturing. Considering that hemp-derived cannabidiol can be used for a multitude of products, the Farm Bill has opened up an entirely new playing field for the cannabis industry.
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Cronos Group Inc (NASDAQ: CRON, TSX: CRON.TO), Canopy Growth Corp (CGC), and Aphria Inc (NYSE:APHA) are four marijuana companies working to take the cannabis industry into the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI) primarily functions as a healthcare company focused on developing innovative healthcare approaches that combine human skill-based expertise with emerging technologies, but recently the Company has made several key investments and acquisitions to strategically enter the cannabis space. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced plans to expand the growth of its development team at Cloud Practice Inc. to support the Company's focus on digitizing health care.
Cronos Group Inc. (CRON) (CRON.TO) (“Cronos Group” or the “Company”) announced that at a Special Meeting held today, the Company’s shareholders overwhelmingly approved the previously announced strategic investment agreement with Altria Group, Inc. (MO) (“Altria”). Pursuant to the agreement, at closing, Altria will make an approximately C$2.4 billion equity investment in Cronos Group (the “Transaction”) on a private placement basis in exchange for common shares (the “Shares”) in the capital of the Company.